Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q4 FY2015 Earnings Presentation
30 slides from Alembic Pharmaceuticals's earnings presentation, April 2015
Slide 1: Investor Presentation
Alembic Pharmaceuticals Limited Investor Presentation April 2015 BSE Code: 533573 NSE Code: APLLTD Bloomberg Code: ALPM:IN Reuters Code: ALEM.NS www.alembic-india.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 3: The Journey so far
The Journey so far 1971 1940 1907 Becomes 1st Indian company to Starts manufacturing cough syrup, Alembic Ltd. starts manufacturing manufacture Erythromycin vitamins, tonics and sculpture drugs tinctures and alcohol at Vadodara 1972 1961 Launched it under brand Penicillin plant inaugurated ‘ALTHROCI
Slide 4: Revenue Overview Q4FY15
Revenue Overview Q4FY15 % of the total sales 2 2 6 India Branded Formulations 15 International Generics 46 API Export India Generics International Branded Formulations 29 API Domestic
Slide 5: Revenue Overview FY 14-15
Revenue Overview FY 14-15 % of the total sales 3 3 6 India Branded Formulations International Generics 15 47 API Export India Generics International Branded Formulations 26 API Domestic
Slide 6: R&D Infrastructure
R&D Infrastructure State-of-the-art Analytical & IPR infrastructure R&D facility F&D Capabilities Bio Equivalence Centre R&D centre has been Expertise in Drug State-of-the art 90- recognized by DSIR, Deliveries and Niche bedded Bio Centre Govt. of India formulations 100 Pilot studies High-end R&D We
Slide 7: R&D spends to continue rising
R&D spends to continue rising Total R&D spend 140 139 R&D spend as a % to sales 7.00 131 7 6.74 120 6 100 4.78 5.06 5 Rs. in Crores 4.06 % of sales 80 77 70 4 60 49 3 40 2 20 1 - 0 FY11 FY11 FY12 FY12 FY13 FY13 FY14 FY14 FY15 FY15 • Highly talented pool of 420 research scientists working to address
Slide 8: State of the Art Manufacturing Facilities
State of the Art Manufacturing Facilities Formulations Located at Panelav, Gujarat USFDA, MCC, MHRA, ANVISA & TPD approved – for Generic exports Capacity - 7 bn tablets / capsules p.a. Located at Baddi, Himachal Pradesh WHO GMP approved Manufactures branded formulations and caters to domestic market
Slide 9: Formulations business accounts for ~80% of revenues
Formulations business accounts for ~80% of revenues
Slide 10: Branded business continues to grow
Branded business continues to grow
Slide 11: Strong domestic market presence
Strong domestic market presence 1.77% market share (Ranked 19th) in Indian formulations market as per IMS MAT data 2 brands featured among Sustained dominance in top 100 and 5 among top anti-infective, analgesics, 300 brands in India as cough and cold segments per IMS MAT data Key Highlights Robust
Slide 12: Continued shift towards Specialty therapies
Continued shift towards Specialty therapies Therapy Dominance 100 90 % of Domestic Formulations 80 44 51 46 70 58 54 60 50 40 30 56 49 54 20 42 46 10 0 FY11 FY12 FY13 FY14 FY15 Specialty Acute
Slide 13: Therapy-wise Performance Q4
Therapy-wise Performance Q4 MAR QTR 2015 MAR QTR 2014 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 14 1.92 37 29 9 1.60 21 37 Anti Diabetic 18 1.55 36 31 20 1.3
Slide 14: Therapy-wise Performance FY 14-15
Therapy-wise Performance FY 14-15 MAR MAT 2015 MAR MAT 2014 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 11 1.77 29 31 12 1.51 27 37 Anti Diabetic 18 1.46 29 27
Slide 15: Marketing Divisions - Specialty
Marketing Divisions - Specialty Corazon Cardio-Diabetes Summit Specia Urology Ouron Alcare Gynecology Zenovi Elena Specialty Enteron Gastroenterology Gastron Dermatology Corium Orthopedics Osteofit Ophthalmology Eyecare High end Respiratory Respiratory
Slide 16: Marketing Divisions
Marketing Divisions Megacare Veterinary Anti-infective Acute and Cold & Pharma Cough Animal Healthcare Maxis Poultry
Slide 17: Key Therapies & Brands
Key Therapies & Brands Therapeutic Segment-wise Break-up (Q4FY15) • Launched 1 product SKU in the domestic market in Q4FY15, 29 product SKUs in FY 2014-15. % of total domestic formulation revenue Brand Name Therapeutic Area Ranking Azithral Anti-infective 33 Althrocin Anti-infective 67 Wikoryl Respi
Slide 18: Branded Export business in investment phase
Branded Export business in investment phase Products filed in key markets (South East Asia, CIS and East Africa) Focus on Rest of the Expected to be of critical World markets mass in 3 years Key Highlights
Slide 19: International Generics will be the growth driver
International Generics will be the growth driver
Slide 20: Fast emerging player in international generics
Fast emerging player in international generics All Facilities approved for supply to regulated markets such as the US, Europe, Australia and Brazil Partnership with leading Launching its own front- generic players in the end marketing in the US US, Europe, Canada, Australia Key Highlights 37 ANDAs/N
Slide 21: API business accounts for ~20% of revenues
API business accounts for ~20% of revenues
Slide 22: Focus on Regulated Markets
Focus on Regulated Markets 30% of capacity being used for captive consumption More than 85% Capacity Key of sales are to expansion is in regulated progress Highlights markets / customers 72 DMFs filed
Slide 23: Financial Snapshot
Aes Financial Snapshot
Slide 24: Focus on shareholder value creation
Focus on shareholder value creation CAGR 85,699 Revenue 16% 100,000 EBITDA 27% 80,000 53,738 In INR mn PAT 31% 60,000 40,000 19,793 Market Capitalization 108% 20,000 20,677 18,684 - 20,000 Market Capitalization 15,260 FY13 FY14 FY15 15,000 In INR mn 10,000 3,577 4,061 2,829 5,000 2,520 1,652 2,355 -
Slide 25: Financial Highlights
Financial Highlights Particulars (INR mn) Q4FY15 Q4FY14 %Growth FY 14-15 FY 13-14 %Growth Formulations Revenue India Branded 2321 1994 16% 9808 8506 15% Generics 321 287 12% 1227 1207 2% International Branded 90 176 -49% 635 736 -14% Generics 1479 1366 8% 5185 4684 11% API Revenue 853 810 5% 3665 33
Slide 26: Latest Shareholding Pattern
Latest Shareholding Pattern % of Total Shareholding 15 Promoter & Promoter group 11 FI/FII/MF 74 Public Market capitalization INR 85 bn Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn No. of shareholders 50 K Free float market capitalization INR 22 bn
Slide 27: Way forward
Aes Way forward
Slide 28: Strategy going forward
Strategy going forward • Continue to focus on complex products. Expect to launch 7-9 products every year for the next three years in the US markets • Create a front-end marketing presence in USA in addition to its existing marketing alliances • Filing ANDAs/MAs in other international markets such as
Slide 29: Conference call details
Conference call details Date : Monday, April 27, 2015 Time : 03.30 pm IST India - Primary Number +91 22 39381028 India - Secondary Number +91 22 67468328 USA 1 866 746 2133 UK 0 808 101 1573 Singapore Toll Free No. 800 101 2045 Hong Kong Toll Free No. 800 964 448
Slide 30: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharm
Alembic Pharmaceuticals — Q4 FY2015 Earnings Presentation on 6ix